On a magic taxi ride. Well, you don't know what we can see. Why don't you tell your dreams to me. Fantasy will set you free...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed! $IMTV is on a roll. Selling out concerts, settling debts, making lucrative partnerships and working with A-list household names.
This opens up the question: are we to expect a new round of private funding for $GTBP?
"Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug. Dr. Vallera said: "I am looking forward to conducting these experiments. Early work suggests that these two agents would be a great combination in the treatment of certain cancers. This initial work will assist us in deciding what tumors to target and the doses to employ.""
It's amazing! OXS 1550 actually targets the antigens on cancer cell and then attacks only those cells with a payload of diptheria toxin. GTBP is brilliant!
We are living in the presence of the future with drugs like OXS 1550 an OXS 3550 coming to market soon. $GTBP is a great way to make money off whats coming next.
Its quite an interesting MTA. This "major phamaceutical company" will supply a formulation of their multibillion $ oncology drug to be used by $GTBP's Vallera in his clinical study. Smells lucrative to me.
Dont know but it pretty darn good news. Wait for this to seep into the market a little deeper.
MAJOR NEWS TODAY: GT Biopharma Inc. Announces Agreement with a Major Pharmaceutical Company to Study its Drug Candidate OXS-1550 in Combination With a Multi-Billion Dollar Oncology Drug
PR Newswire
LOS ANGELES, July 19, 2018
LOS ANGELES, July 19, 2018 /PRNewswire/ --
GT Biopharma Inc. (GTBP) and (Euronext Paris: GTBP.PA) announced today a Material Transfer Agreement (MTA) between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota.
Under the terms of the agreement, this Major Pharmaceutical Company will supply a formulation of their multibillion dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.
Dr. Vallera is the lead researcher for GT Biopharma's bispecific antibody drug conjugate (ADC) program, and the innovator of oncology drug candidate DT2219, also known as OXS-1550. OXS-1550 targets two antigens on cancer cells and contains a cytotoxic payload thereby increasing the probability it will kill the cancer cells. OXS-1550 targets cancer cells expressing the CD19 receptor and/or CD22 receptors which includes B-cell leukemias and lymphomas and has a modified form of diphtheria toxin (DT390) as its cytotoxic drug payload. After OXS-1550 binds to cancer cells, it is taken in by the cancer cells and subsequently deploy its cytotoxic diphtheria toxin payload which inhibits protein synthesis and kills the cancer cells.
Initial pre-clinical work performed by Dr. Vallera suggests a much greater effect when OXS-1550 is given in combination with this established oncology drug. Dr. Vallera said: "I am looking forward to conducting these experiments. Early work suggests that these two agents would be a great combination in the treatment of certain cancers. This initial work will assist us in deciding what tumors to target and the doses to employ."
GT Biopharma's Chairman and Chief Executive Officer (CEO) Dr. Raymond Urbanski said: "This is a tremendous step forward for the OXS-1550 program. Pre-clinical data suggests that the combination of OXS-1550 and this agent is highly potent against certain tumor cell lines. This MTA will allow further studies in animal models to both confirm the effects as well as ascertain which tumor types are the most susceptible to this potent combination."
About GT Biopharma, Inc.:
GT Biopharma, Inc. is a biotechnology company focused on innovative drugs for the treatment of cancer. GT's lead oncology drug candidate, OXS-1550 (DT2219) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or the CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. In addition, GTs TriKE platform will address a number of cancer types. GT's nervous system platform is focused on acquiring or discovering and patenting late-stage, de-risked, and close-to-market improved treatments for nervous system diseases (Neurology and Pain) and shepherding them through the approval process to the NDA. GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company website: https://www.gtbiopharma.com/
Contact:
Westwicke Partners
John Woolford
+1(443)-213-0506
john.woolford@westwicke.com
SOURCE GT Biopharma Inc.
Check out Urbanski's Bio: RAYMOND URBANSKI, M.D., PH.D.
Chief Executive Officer and Chairman
Dr. Urbanski spent eight years with Pfizer and held several positions with the company, including Vice President/CMO of the Established Products Business Unit, senior medical director of oncology clinical R&D, senior medical director of breast cancer products and medical director of diversified products. He brings extensive experience in developing and overseeing clinical studies, including phase 3b and phase 4 studies (including line extensions) for sunitinib (Sutent), exemestane (Aromasin), irinotecan (Camptosar), epirubicin (Ellence), axitinib, IGF1R inhibitor, and tremilimumab. In addition to his role with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of Metabolex Inc., and Senior Director of US Medical Affairs for Aventis.
Yeah the tech as it is on paper before the clinical trial results are published, patents and such. All of that is already worth more than $GTBP is trading at.
Yes this is still massively undervalued when you consider all the new therapies coming down the pipeline. The IP alone would put this at $4 IMHO.
Urbanski is eminently qualified and the right CEO to guide both guiding the therapy pipeline to market, but also getting $GTBP uplisted to the NASDAQ board where it belongs
Staying above 2. The HOD at 23 is a strong indicator of what we'll see at open tommorow.
Looking for a strong opening this morning for IMTV.
Tekashi69 is a whirlwind of drama, but he sure knows how to keep the media's attention. $IMTV understands all publicity is good publicity.
Keep $GTBP in your sights. Immunooncology play here has a major product pipeline that will utterly disrupt the cancer treatment industry. Hugely undervalued.
Long and strong and super bullish on $GTBP.
OXS 3550 looks like it could be even more impressive than OXS 1550.
Second half of 2018 should be phenomenal for $GTBP..
The share structure here is set to really run. We have the right CEO now to manage an uplisting.
Immunooncology is the future of cancer treatment. $GTBP is sitting massive lucrative upside.
$GTBP keep your eyes glued here, Reestablishing support at 2. Immunuoncology drug pipeline makes this way underrated. New MOMO coming.
$GTBP sideways so far but nice to see it holding at 2.
$IMTV green 4%! lets see a new HOD before close.
Im thinking even beyond that. The positive fallout from LIT Up FEST should continue as they disclose revs perhaps.
That would be great. It would mean nationwide level recognition for IMTV I'd think.
One thing I know for sure these cheap levels wont last long. $IMTV is making a big successful splash into the very lucrative concert promotion biz and the revenues will be pouring in. They've already made sweet revs in Cincinatti and about to in Miami. Once we start seeing these posted in financial reports this wont stay sub penny forever.
They definitely wont last forever. Especially once we get the details on the revenues from the LIT UP Music Festival.
YES! 2 breakout! time we make this our new support level. $GTBP
No more wondering which is worse right? The disease or the treament. $GTBP promises massive upside potential for her investors IMHO.
Yeah and the end result of how OXS -1550 targets only cancer cells specifically is paitents are able to get well without the chemo drugs meant to cure them damaging thier entire system with side effects. $GTBP holds the key to the future of cancer treatment.
I wonder if they are getting ready to announce Phase 2 results for OXS-1550? That could be massive news coming down the pike for $GTBP and investors who go on the right side of that reveal would be sitting pretty.
$IMTV still has 2 weeks till LIT Up Fest, the grass roots marketing buzz will amp up exponentially every day and you'll see retail start lining up. Grab it low before we bust 5's is MHO.
Yup. Grassroots buzz is really starting to heat up for $IMTV. Even these Twitter shenanigans with Tekashi69 is just more shock value publicity that will play out in our favor.
I think tommorow we should see a major $IMTV run right out of the gate.
Seriously?!? $IMTV has now actively wiped $170k in debt off the books thus preventing dilution according to a company tweet today. Great news for $IMTV investors!
Wow, thats good news. Can he actually guarentee that though? It would be great of course for IMTV.
Wow! thats awesome!
$IMTV selling out tier 1. Looks like if we sell out the rest of the concert then add concessions there could be a cool million in revs netted from just the LIT UP Music Fest. Wow!
Nice 10% Green close here for $IMTV. I think the market is finally seeing what we've all been seeing. $IMTV